A Phase 1 Study of BG-60366 in People With Advanced Non-Small Cell Lung Cancer

Full Title

Phase 1a/1b, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of a CDAC Degrading EGFR, BG-60366, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Purpose

Researchers want to find the best dose of BG-60366 to treat advanced lung cancer. The people in this study have non-small cell lung cancer (NSCLC) that has spread. In addition, their tumors have a mutation (change) in the EGFR gene.

BG-60366 is designed to break down the mutated EGFR protein, which promotes the growth of NSCLC. BG-60366 is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have EGFR-mutated NSCLC that keeps growing after standard treatment.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

 

Contact

For more information or to see if you can join this study, please call Dr. Helena Yu’s office at 646-608-3912.